Induction chemotherapy before surgery for early-stage lung cancer: A novel approach  by Pisters, K.M.W. et al.
429
stage T2 N0, T1-2 N1, and T3 N0-1 NSCLC have poor
5-year survivals (38%, 34%, 24%, 22%, and 9%, respec-
tively).2 Although the disease is presumed to be confined
to the chest, it recurs in the majority of patients under-
going resection, and they die of metastases. Trials eval-
uating postoperative radiotherapy, chemotherapy, or
I n 1999, lung cancer will be diagnosed in an estimated171,600 patients.1 Of these new cases, approximately
80% will have non–small cell lung cancer (NSCLC).
Although the most common presentation is metastatic
disease, many patients present with potentially operable
disease. Despite surgical resection, patients with clinical
Objective: This phase II trial assessed the feasibility, as measured by
response rate, toxicity, resectability rate, and surgical morbidity and
mortality rates, of perioperative paclitaxel and carboplatin chemothera-
py in patients with early-stage non–small cell lung carcinoma. Methods:
All patients required negative mediastinoscopy results and adequate
medical parameters to undergo induction chemotherapy and an opera-
tion. Superior sulcus patients were excluded. Chemotherapy consisted of
paclitaxel 225 mg/m2 over 3 hours and carboplatin (area under the curve
= 6) every 21 days for 2 cycles preoperatively. Three postoperative cycles
of chemotherapy were planned for patients undergoing complete resec-
tion. Results: Between June 1996 and July 1998, 94 patients were entered
into the study. Sixty-five (69%) were men, and the median age was 64
years (range, 34-79 years). After induction chemotherapy, 53 of 94 (56%;
95% confidence interval, 46%-67%) had a major objective response, 88
(94%) underwent surgical exploration, and 81 (86%; 95% confidence
interval, 78%-92%) underwent complete resection. Reasons for not
undergoing an operation included disease progression (n = 3), clinically
unresectable status (n = 1), death (n = 1), and patient lost to follow-up
(n = 1). Two postoperative deaths occurred. Six (6%; 95% confidence
interval, 0%-13%) pathologic complete responses were observed. Ninety
(96%) patients received the planned preoperative chemotherapy versus
45% receiving postoperative chemotherapy. No unexpected chemothera-
py or surgical morbidity occurred. The 1-year survival is currently esti-
mated at 85%, and the median survival has not yet been reached.
Conclusions: Induction chemotherapy with paclitaxel and carboplatin is
feasible and produces a high response rate with acceptable morbidity
and mortality rates in early-stage non–small cell lung carcinoma. A
prospective randomized trial comparing 3 cycles of induction chemother-
apy and surgery with surgery alone in early-stage non–small cell lung
carcinoma is planned. (J Thorac Cardiovasc Surg 2000;119:429-39)
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both in resectable NSCLC have been disappointing. In
contrast, randomized trials have demonstrated improved
survivals for patients with locally advanced disease
treated with cisplatin-based induction chemotherapy
before radiation therapy3,4 or surgery.5,6 Given the sur-
vival statistics and failure of postoperative treatment to
substantially improve outcome for patients with early-
stage resectable NSCLC, this trial was designed to
explore perioperative chemotherapy in patients with
clinical stage IB (T2 N0), II (T1-2 N1, T3 N0), and
selected IIIA (T3 N1) disease extent.
The chemotherapy regimen of paclitaxel and carbo-
platin has been extensively studied in cases of metasta-
tic NSCLC.7-13 This combination has been found to be
well tolerated. The most severe toxicities are neutrope-
nia and peripheral neuropathy, which are observed in
the minority of patients who generally receive 3 to 4
cycles. The data from all of these studies suggest that
the combination of paclitaxel and carboplatin is active.
We elected to use a 3-hour paclitaxel schedule because
it can be given on an outpatient basis without routine
growth factor support. The response rates with 225
mg/m2 given over 3 hours appear equivalent to those
observed with the more myelosuppressive 24-hour
infusions by using lower doses.
Two cycles of preoperative chemotherapy were
planned because most responses in metastatic disease
had been observed after 2 cycles of chemotherapy7-13
and to avoid excessive delay before surgery in this
early-stage group of patients. Three cycles of postoper-
ative chemotherapy were incorporated into the study
design because the randomized trial by Roth and col-
leagues5 for stage III disease had used both preopera-
tive and postoperative chemotherapy, and the majority
of the planning committee recommended additional
chemotherapy for patients experiencing major tumor
regression after the 2 preoperative cycles.
The main objective of this study was to establish the
feasibility, as measured by the response rate and toxic-
ity of perioperative chemotherapy, resectability rate,
pathologic complete response (CR) rate, and surgical
mortality rate, of a perioperative regimen of paclitaxel
and carboplatin in patients with early-stage NSCLC. A
secondary objective was to prospectively estimate the
survival of patients with NSCLC treated with this
approach, with a view toward a randomized trial com-
paring perioperative chemotherapy plus surgery with
surgery alone.
Methods
From June 1996 to July 1998, 94 patients with histologi-
cally confirmed NSCLC were entered into this multicenter
trial. All patients had clinical stage T2 N0, T1-2 N1, or T3
N0-1 NSCLC, as defined by history, physical examination,
routine laboratory evaluation, chest computed tomography
(CT) scan, bronchoscopy, and mediastinoscopy. Clinical T
stage was defined by CT imaging. Clinical nodal stage was
assessed by mediastinoscopy and CT imaging. A negative
biopsy result of all enlarged (>1.0 cm on CT scan) mediasti-
nal lymph nodes was required. Clinically involved N1 nodes
(level 10 hilar, 11, 12, and 13) were defined as having a short
diameter greater than 1.0 cm on CT scan confirmed by a radi-
ologist. Patients with superior sulcus tumors were excluded
because of a competing study. Patients were required to have
no prior chemotherapy or radiation therapy, be 18 years or
older, have Zubrod performance status of 0 to 1, and have
adequate hematologic, renal, and hepatic function to safely
undergo chemotherapy and surgery. Patients were also
required to have a predicted postresection forced expiratory
volume in 1 second of 1.0 L or more and bidimensionally
measurable disease or evaluable indicator lesions. Informed
consent was obtained from all patients, and the protocol was
reviewed and approved by the institutional review board of
each participating institution.
Pretreatment evaluation included a CT scan of the chest
and upper abdomen (to include the adrenal glands), postero-
anterior and lateral chest x-ray films, electrocardiograms,
pulmonary function tests (spirometry, arterial blood gas, and
diffusing capacity), bronchoscopy, and mediastinoscopy in
addition to routine laboratory tests. Imaging studies of the
brain and bone were required only if clinically indicated. All
toxicities were graded according to Southwest Oncology
Group toxicity criteria.
Treatment plan
Preoperative chemotherapy. Eligible patients received 2
cycles of preoperative chemotherapy with paclitaxel (225
mg/m2 as a 3-hour intravenous infusion) and carboplatin
(area under the curve of 6, as determined by the Calvert for-
mula; administered intravenously over 30 minutes after the
paclitaxel infusion) every 21 days. Before the second cycle of
chemotherapy, patients had repeat laboratory tests and a chest
x-ray film. Patients with evidence of disease progression after
1 or 2 cycles of preoperative chemotherapy were removed
from protocol treatment and recommended for surgical
exploration if appropriate. All patients were premedicated for
chemotherapy with a combination of dexamethasone, diphen-
hydramine, and an H2 antagonist according to standard prac-
tice. No dose escalation was allowed. Subsequent doses of
chemotherapy were modified for toxicity if appropriate. A
major objective response after induction chemotherapy con-
sisted of complete response (CR) or partial response (PR).
CR was defined as total resolution of all radiographic find-
ings after chemotherapy, and PR was recorded when the sum
of the products of perpendicular diameters of all measurable
lesions was reduced by 50% or more from baseline. Progres-
sive disease was defined as a 50% increase in the product of
the tumor diameters or appearance of any new lesion. All
other patients were considered to have stable disease.
Surgery. Patients without evidence of progressive disease
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underwent thoracotomy within 3 to 6 weeks of their second
administration of paclitaxel and carboplatin. A repeat staging
evaluation 2 to 6 weeks after the second paclitaxel and car-
boplatin administration was performed and included the fol-
lowing: bronchoscopy (for patients with T3 N0 disease
assessable only by bronchoscopy), repeat pulmonary func-
tion tests, electrocardiograms, chest x-ray films, and a CT
scan of the chest and upper abdomen.
At thoracotomy, the extent of pulmonary resection was left
to the discretion of the attending surgeon as long as the resec-
tion chosen provided complete removal of the primary lesion
with negative gross and microscopic margins (R0).
Segmentectomy and wedge resection were discouraged. All
accessible hilar lymph nodes were dissected from the speci-
men, and a complete mediastinal lymph node dissection was
performed in all patients. For right-sided lesions, this includ-
ed 2R, 4R, 7, 8, 9, and 10R. For left-sided lesions, this includ-
ed 4L, 5, 6, 7, 8, 9, and 10L.
Postoperative chemotherapy and follow-up. Patients who
did not undergo complete resection (positive microscopic
margins, R1; gross disease, R2) and were found to have dis-
eased (positive) mediastinal nodes, T4 lesions, or metastatic
disease at surgery were removed from protocol treatment.
Patients who had unacceptable morbidity were removed from
study treatment and received further therapy at the discretion
of their physicians. All patients were followed up to ascertain
recurrence, long-term toxicities, and survival. Patients who
underwent complete resection and whose disease did not
progress on induction chemotherapy were to receive 3 cycles
of postoperative paclitaxel and carboplatin chemotherapy
(same dose and schedule as preoperative cycles) beginning
within 8 weeks of thoracotomy. After completion of protocol
therapy, patients were followed up with an interval history,
physical examinations, and chest x-ray films every 3 months
for 1 year and then every 6 months thereafter.
Statistical considerations. The main objective of this trial
was to establish the feasibility of perioperative paclitaxel and
carboplatin treatment in patients with clinical stage IB, II,
and selected IIIA NSCLC. The key end points were response
rate and toxicities of chemotherapy, pathologic CR rate,
resectability rate, and surgical morbidity and mortality rates.
With an accrual of 80 patients, the resectability rate,
response rate, and surgical mortality rate could be estimated
to within ±11% (approximate 95% confidence interval [CI]).
A preliminary assessment of the primary study end points
occurred after the initial 20 eligible patients had undergone
surgery and had been followed up for 1 month. No unex-
pected morbidity or mortality had occurred, and the protocol
continued to enroll patients. Time to progression and sur-
vival were calculated as the elapsed time between the date of
registration for study and the first documentation of recur-
rence or death, respectively. All patients will be followed up
until death.
Results
Ninety-four patients were accrued, with a median age
of 64 years. Sixty-five (69%) patients were male (Table
I). Patients had a Zubrod performance status of 0 or 1.
Pretreatment clinical disease stage was as follows: T2
N0, 42 patients; T1 N1, 1 patient; T2 N1, 27 patients,
T3 N0, 17 patients, and T3 N1, 7 patients. Squamous
cell carcinoma was the most frequent histologic sub-
type (44%). Twelve (13%) patients had an elevated
serum lactate dehydrogenase level at study entry.
Induction chemotherapy. Ninety (96%) patients
received both cycles of paclitaxel and carboplatin pre-
operatively. Four patients did not complete induction
treatment. Three patients were removed from the study
because of allergic reactions to paclitaxel, and 1 patient
died of a cerebrovascular accident after the first cycle
of induction chemotherapy (see below).
Response to induction chemotherapy. The radio-
graphic response to induction chemotherapy is present-
ed in Table II. One patient had a clinical CR, and 52
patients had PRs. The overall major objective clinical
Table I. Patient characteristics
No. of patients 94
Median age, y (range) 64 (34-79)
Men (%) 65 (69)
Women (%) 29 (31)
Zubrod performance status (%)
0 50 (53)
1 44 (47)
Pretreatment clinical stage (%)
IB, T2 N0 42 (45)
IIA, T1 N1 1 (1)
IIB, T2 N1 27 (29)
IIB, T3 N0 17 (18)
IIIA, T3 N1 7 (7)
Histology (%)
Squamous cell carcinoma 41 (44)
Adenocarcinoma 32 (34)
NSCLC, not otherwise specified 16 (17)
Large cell carcinoma 5 (5)
Elevated serum lactate dehydrogenase (%)* 12 (13)
*Measurements for 3 patients were not available.
Table II. Induction chemotherapy response
No. % 95% CI
CR 1 1
PR 52 55
Major response 53 56 46-67
Stable disease 32 34
Progression 3 3
Not evaluable 6*
Total 94
*There were 2 paclitaxel reactions, 2 patients with inadequate data, 1 patient
lost to follow-up, and 1 induction death.
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response rate after induction chemotherapy was 56%
(95% CI, 46%-67%). Stable disease was seen in 32
(34%) patients, and disease progression was seen in 3
(3%). Six patients were not evaluable for response to
induction chemotherapy. Two had paclitaxel reactions
during their first cycle of chemotherapy, 2 had inade-
quate imaging data, 1 was lost to follow-up, and 1 died.
Surgical treatment. After chemotherapy, 88 (94%)
of the 94 patients underwent surgical exploration.
Reasons for not undergoing surgical exploration are
Table III. Surgical results
Clinical No. of No Pathologic
stage patients surgery Explored R0 CR
T2 N0 42 2* 40 38 3
T1 N1 1 0 1 1 1
T2 N1 27 1† 26 26 2
T3 N0 17 1‡ 16 12 0
T3 N1 7 2§ 5 4 0
Total (%) 94 6 (6) 88 (94) 81 (86) 6 (6)
95% CI 78%-92% 0%-13%
R0, Complete resection.
*One patient had progression of disease, and there was 1 induction death.
†One patient had progression of disease.
‡One patient had clinically unresectable disease.
§One patient had progression of disease, and 1 patient was lost to follow-up.
Table IV. Surgical treatment
Treatment No. of patients
Lobectomy 68
Lobectomy 58
Lobe plus chest wall 7
Lobe plus sleeve 3
Pneumonectomy 13
Simple 9
Pneumonectomy plus chest wall 2
Intrapericardial pneumonectomy 2
Bilobectomy 4
Exploration only 2
Wedge resection 1
Total 88
Table V. Correlation of clinical and pathologic staging
Pathologic (surgical) stage
Clinical stage Explored Less extensive Equivalent More extensive
T2 N0 (n = 42) 40 12 (30%) 7 (17%) 21 (53%)
T0 N0 = 3 T3 N0 = 3
T1 N0 = 9 T4 N0 = 1
T1 N1 = 3
T2 N1 = 5
T3 N1 = 1
T4 N1 = 1
T2 N2 = 5
T2 N0, T1 N0 = 1
T3 N0 M1 = 1
T1 N1 (n = 1) 1 1 (100%)
T0 N0 = 1
T2 N1 (n = 27) 26 16 (62%) 4 (15%) 6 (23%)
T0 N0 = 2 T3 N1 = 1
T1 N0 = 6 T4 N0 = 1
T2 N0 = 6 T2 N2 = 3
T0 N1 = 1 T2 N0, T1 N0 = 1
T1 N1 = 1
T3 N0 (n = 17) 16 8 (50%) 3 (19%) 5 (31%)
T1 N0 = 4 T3 N1 = 2
T2 N0 = 3 T3 N2 = 1
T2 N1 = 1 T3 N3 = 1
T4 N1 = 1
T3 N1 (n = 7) 5 5 (100%)
T1 N0 = 1
T2 N0 = 2
T3 N0 = 2
Total 88 42 (48%) 14 (16%) 32 (36%)
Less extensive, Pathologic stage less extensive than clinical stage; equivalent, pathologic stage the same as the clinical stage; more extensive, pathologic stage more
extensive than clinical stage.
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listed in Table III. Complete resection (R0) of all resid-
ual tumor at the primary site and in lymph nodes was
possible in 81 patients (86%; 95% CI, 78%-92%). The
types of resection included lobectomy in 68, pneu-
monectomy in 13, bilobectomy in 4, exploration only
in 2, and wedge resection in 1 patient (Table IV).
Surgical pathologic findings for each subset of clini-
cally staged patients are presented in Table V.
Pathologic CR observed in 6 patients (6%; 95% CI,
0%-13%) occurred only among major responders clin-
ically. Overall, 48% of patients had a pathologic stage
that was less extensive than their pretreatment clinical
stage, 16% had an equivalent stage, and 36% had more
extensive disease. Of the 42 patients whose pathologic
stage was less than their clinical stage at protocol entry,
30 (71%) had a radiographic major response to induc-
tion therapy (Table VI). Fifty percent of patients who
were found to have equivalent or more extensive dis-
ease at surgery had major chemotherapy responses.
Postoperative treatment. Forty-three (46%) patients
did not receive postoperative chemotherapy. Twenty-
eight were considered to be “off study” because of sur-
gical pathologic findings (19), no surgery (6), or prior
paclitaxel reaction (3). Fifteen patients who were con-
sidered “on study” did not receive postoperative
chemotherapy because of prolonged postoperative
recovery/complications (6), poor performance status
(2), postoperative death (2), neuropathy (1), elevated
Table VI. Pathologic staging versus clinical response
Pathologic stage
Less Equivalent More
Clinical stage No. of patients Explored PR SD PR SD PR SD
T2 N0 42 40 10 2 2 5* 10 11
T1 N1 1 1 1 0 0 0 0 0
T2 N1 27 26 10† 6 4 0 4 2
T3 N0 17 16 4 4‡ 1 2 2 3§
T3 N1 7 5 5 0 0 0 0 0
Total 94 88 30 12 7 7 16 16
Major response rate 30/42 (71%) 7/14 (50%) 16/32 (50%)
PR, Partial response (≥50% decrease in the product of the tumor diameters); SD, stable disease.
*One patient was not evaluable for clinical response (paclitaxel reaction).
†One patient had a clinical CR.
‡Two patients were not evaluable for clinical response (paclitaxel reaction).
§Two patients were not evaluable for clinical response (inadequate data).
Table VII. Induction chemotherapy toxicity (n = 94)
Grade
Toxicity Unknown 0 1 2 3 4 5
Allergy 1 88 0 2 1 2 0
Hematologic
Anemia 1 41 44 7 0 1 0
Granulocytopenia 1 29 14 17 16 17 0
Thrombocytopenia 1 83 9 0 1 0 0
Infection 1 85 1 1 6 0 0
Malaise/fatigue/lethargy 1 55 22 16 0 — —
Myalgia/arthralgia 1 38 26 24 5 — —
Nausea 1 68 15 9 1 0 0
Neuropathy
Numbness 2 82 0 9 1 0 0
Paresthesia 1 60 28 2 3 0 0
Phlebitis/thrombosis/embolism 1 91 0 1 0 0 1
Vomiting 1 79 7 6 1 0 0
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liver transaminase level (1), discovery of metastatic
disease (1), being lost to follow-up (1), and inadequate
data (1). Forty-two (45%) patients received all 3 of the
planned postoperative paclitaxel and carboplatin
chemotherapy cycles. Eight (8%) patients received
only 2 cycles because of treatment-limiting fatigue (3),
neuropathy (2), error (1), physician decision to begin
radiotherapy (1), and an unknown cause (1). One
patient received only 1 cycle because of treatment lim-
iting neuropathy. Of the 66 patients potentially eligible
to receive postoperative chemotherapy, 42 (64%)
received all 3 cycles.
Treatment-related complications. Table VII dis-
plays the significant toxicities observed during the 2
cycles of induction chemotherapy. Three patients expe-
rienced grade 3 or 4 paclitaxel-induced hypersensitivi-
ty reactions. Severe anemia or thrombocytopenia
occurred in only 1 patient each. Grade 3 or 4 neutrope-
nia occurred in 35% of patients; however, no patient
was admitted with febrile neutropenia. Forty-one per-
cent of patients complained of grade 1 or 2 fatigue, but
none had grade 3 fatigue. Myalgias and arthralgias
were common, with 26 (28%) patients reporting grade
1 (mild), 24 (26%) reporting grade 2 (decreased ability
to move), and 5 (5%) reporting grade 3 (disabling).
This complication generally occurred several days after
chemotherapy and resolved within 1 week. Nausea and
vomiting were uncommon. Peripheral neuropathy of
moderate severity was noted in 4 patients (4%), and
none had grade 4 neuropathy.
There was one death during induction chemotherapy.
This occurred in a 71-year-old woman after recovery
from chemotherapy-related toxicity. The patient was
hospitalized after the first cycle of chemotherapy with
grade 4 neutropenia, hyponatremia, and mental status
changes. The patient had seizures and was believed to
have had a cerebrovascular accident. After resolution of
her neutropenia and hyponatremia, the patient was dis-
charged to a nursing facility, where she died after
extension of her cerebrovascular accident.
Table VIII displays the surgical morbidity data. No
unusual toxicities were noted. In all patients pulmonary
function tests were performed before protocol entry
and again before surgery. There were no significant
changes in these tests. There were 2 postoperative
deaths. One occurred in a 61-year-old man with clini-
cal T2 N1 disease. This patient experienced a PR after
chemotherapy, underwent lobectomy with complete
resection, and was found to have T2 N0 disease at
surgery. On postoperative day 4, the patient became
febrile and had progressive shortness of breath necessi-
tating intubation. The patient died after a prolonged
stay in the intensive care unit. The second postopera-
tive death occurred in a 69-year-old man with clinical
T2 N0 disease. This patient had a PR to induction ther-
apy and underwent complete resection with pneu-
monectomy but had T2 N2 disease at surgery. On post-
operative day 1, the patient became acutely short of
breath requiring reintubation and died shortly there-
after. The presumed cause of death was a pulmonary
embolus.
Postoperative chemotherapy toxicity data are dis-
played in Table IX. No additional or unexpected toxic-
ities occurred.
Survival. Survival data are presented in Fig 1. The 1-
and 2-year survivals for the 94 patients were 85% and
56%, respectively. The median survival has not yet
been reached. Interpretation of this survival curve is
hampered by the relative nonhomogeneity of the clini-
cal/pathologic stages of the patients treated.
Discussion
Patients with clinically staged T2 N0, T1 N1, T2 N1,
and T3 N0-1 NSCLC have poor 5-year survival (38%-
9%) when treated with surgery alone.2 Overall results
with postoperative chemotherapy have found a 5% or
less improvement in survival at 5 years.14 Postoperative
radiotherapy has not been shown to improve survival.15
In the past decade numerous phase II trials have
examined the use of induction chemotherapy (with or
without radiotherapy) followed by surgery for stage III
NSCLC.16-19 Induction therapy offers several poten-
tial advantages, including (1) early control of micro-
metastatic disease, (2) reduction in size of the primary
tumor, (3) patient acceptance (vs postoperative thera-
py), and (4) patient compliance because of better toler-
ability. These single-institution trials found that preop-
erative chemotherapy was feasible and resulted in
higher response rates than previously seen in patients
with stage IV disease. In patients with stage III disease
so treated, complete resection rates ranged from 50% to
75%, and pathologic CRs (no viable tumor found in the
resection specimen) were found in 5% to 15% of
patients. Pathologic CR is predictive of long-term sur-
vival.20 Median survivals reported in these studies were
comparable (18-24 months), with 5-year survivals from
15% to 25%.
Two prospective randomized trials have compared
primary surgery with induction chemotherapy and
surgery in stage IIIA NSCLC.5,6 Both trials were ter-
minated early after interim analyses indicated a sur-
vival advantage for the chemotherapy-treated patients.
Cisplatin-based chemotherapy was administered pre-
operatively for 3 cycles in each trial, and an additional
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3 cycles of chemotherapy were given postoperatively to
the patients in the M. D. Anderson study. Postoperative
irradiation was given to all patients in the Spanish trial
and only to patients having incomplete resection in the
M. D. Anderson trial. Response to induction
chemotherapy was 60% in the Barcelona study and
35% in the M.D. Anderson study. Both trials showed a
significant improvement in survival for patients treated
with induction chemotherapy. This survival advantage
persisted with multivariate analysis and long-term
follow-up.
On the basis of the success of induction chemothera-
py before surgery in stage III NSCLC, we and others
have designed studies to evaluate the role of induction
chemotherapy before surgery in earlier-stage NSCLC.
Depierre and colleagues21 from France have reported
preliminary results of a randomized trial of induction
chemotherapy with mitomycin, ifosfamide, and cis-
platin plus surgery compared with surgery alone in
stages IB, II, and IIIA NSCLC. A total of 373 patients
were entered into the study, and 355 were eligible. One
hundred eighty-eight had stage I or II disease, whereas
167 had stage IIIA disease. Pathologic CRs occurred in
19 (11%), and pathologic downstaging occurred in a
further 95 (54%) of the patients treated with
chemotherapy. A 10-month improvement in the median
survival (26 vs 36 months, P = .11) was seen.
Postoperative morbidity was more common in the com-
bined modality arm, with an increased rate of fistula
and empyema observed. The postoperative mortality
rate was also increased in the combined modality arm,
but this was not statistically significant. Survival was
then separately examined within the first 150 days and
thereafter because of nonproportional hazards over
Table VIII. Surgical toxicity (n = 88)
Grade
Toxicity Unknown 0 1 2 3 4 5
Arrhythmia 8 67 1 1 9 2 0
Hemorrhage 7 80 0 0 1 0 0
Lung (other) 13 56 2 5 10 1 1
Phlebitis/thrombosis/embolism 7 80 0 0 0 0 1
Pneumonitis/effusions/infiltrates 12 72 1 1 2 0 0
Pulmonary edema 7 79 0 0 2 0 0
Respiratory infection 7 70 0 1 10 0 0
Wound infection 7 80 0 0 1 0 0
Table IX. Postoperative chemotherapy toxicity (n = 51)
Grade
Toxicity Unknown 0 1 2 3 4 5
Allergy 0 51 0 0 0 0 0
Hematologic
Anemia 4 23 22 2 0 0 0
Granulocytopenia 4 12 9 3 10 13 0
Thrombocytopenia 4 31 13 3 0 0 0
Infection 4 46 1 0 0 0 0
Malaise/fatigue/lethargy 4 23 9 13 2 — —
Myalgia/arthralgia 4 29 5 11 2 — —
Nausea 4 37 5 4 1 0 0
Neuropathy
Numbness 4 30 0 12 5 0 0
Paresthesia 4 29 14 3 1 0 0
Phlebitis/thrombosis/embolism 4 47 0 0 0 0 0
Vomiting 4 42 1 2 2 0 0
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time in treatment groups. After a nonsignificant excess
of deaths in the combined modality arm during the
treatment period, the effect of combined modality ther-
apy after 150 days was significantly favorable for sur-
vival. No difference was seen in local recurrence rate;
however, a significant decrease in distant metastases
was seen favoring the chemotherapy arm. Disease-free
survival was significantly longer in the chemotherapy
arm (P = .02). The authors concluded that the use of
combined modality therapy resulted in a significant
decrease in the risk of death for patients with early-
stage NSCLC, and a significant survival benefit was
seen beyond 5 months.
The clinical response rate of 56% seen in this multi-
institutional trial may seem low in comparison with the
phase II experience of cisplatin-based chemotherapy in
stage III disease. However, this response rate is more
than double the 22% response rate seen in the multi-
institutional trial comparing paclitaxel and carboplatin
(same dose and schedule) to etoposide and cisplatin in
patients with inoperable disease.22 The pathologic CR
rate of 6% is lower than that seen for cisplatin-based tri-
als in patients with stage III NSCLC. However, many
patients had evidence of pathologic downstaging but did
not fulfill the criteria for complete histologic steriliza-
tion. The randomized trial comparing induction pacli-
taxel and carboplatin with surgery alone will include 3
cycles of preoperative chemotherapy, which we hope
will improve the major response and pathologic CR
rates.
This trial also serves to emphasize that despite mod-
ern CT imaging and mediastinoscopy, clinical staging
was inaccurate, with only 16% of patients having an
equivalent clinical and pathologic stage and 36% hav-
ing more extensive disease at surgery (Table V). Some
of this inaccuracy may have been due to a positive
downstaging effect of the chemotherapy. The routine
use of positron emission tomography (PET) scanning
may improve the diagnostic accuracy of clinical stag-
ing in the future. Use of PET scanning will be encour-
aged but not required for the planned phase III trial.
Ninety-six percent of the enrolled patients received
the induction chemotherapy as planned. In contrast,
only 43 (46%) of the patients enrolled received the
planned 3 postoperative cycles of chemotherapy. Of
the 66 patients who were potentially eligible to receive
the postoperative chemotherapy (ie, not off study for
pathologic/surgical stage, progression on induction
chemotherapy, or paclitaxel allergic reaction), only 42
(64%) received the full 3 cycles. This experience is
similar to that seen in other postoperative adjuvant tri-
als conducted in stage III NSCLC using high-dose cis-
platin chemotherapy,23-25 during which patients were
often unable to receive the entire prescribed dose.
This multi-institutional phase II trial has demon-
strated that induction chemotherapy with paclitaxel and
carboplatin is feasible and safe in early-stage
NSCLC. Response rates and pathologic findings sug-
gest promise for this approach in improving survival in
early-stage resectable NSCLC. Induction chemothera-
py before surgery may provide the best approach for
using combined modality therapy in the management
of NSCLC.
A phase III North American intergroup trial compar-
ing primary surgery alone with induction chemothera-
py with paclitaxel and carboplatin followed by surgery
is planned. This national trial is anticipated to open in
1999.
Fig 1. Overall survival curve.
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Discussion
Dr Mark K. Ferguson (Chicago, Ill). Dr Pisters, you and
your co-authors have performed an important clinical trial
aimed at determining the potential benefit of neoadjuvant
chemotherapy in early-stage NSCLC. As surgeons, our
inability to achieve adequate cure rates with the single-
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modality therapy of resection, even in early-stage lung can-
cer, has been evident for decades. The reluctance of the sur-
gical and medical communities to investigate multimodality
therapy has been based on the relatively low efficacy of tradi-
tional multiagent regimens and the high toxicity associated
with them. New agents and combinations permit outpatient
therapy with relatively low toxicity, have improved patient
acceptance, and demonstrate good clinical response rates,
thus providing the opportunity for studies such as this.
Your report is a valuable one, demonstrating that a trial of
neoadjuvant chemotherapy for early-stage lung cancer can
accrue patients successfully and produces relatively good
clinical response rates with low morbidity. These are the
results the authors predicted but form an important basis for
future work. The results also raise some interesting questions. 
First, is this the right subset of patients to select for neoad-
juvant therapy? In particular, why do you omit patients with
stage IA disease, whose survival is only marginally better
than that of patients with stage IB disease? Also, why include
patients with T3 disease who had an R0 resection rate of only
60% and who accounted for a large fraction of the patients
taken off the protocol? Would it not be best to concentrate on
patients with T1 or T2 or N0 or N1 disease so as not to muddy
the waters? 
Second, in the presentation and in the article constant ref-
erence is made to clinical stage rather than pathologic stage.
Unfortunately, even with routine mediastinoscopy, clinical
staging in this trial was less than 20% accurate, with at least
35% of patients being understaged. Did you consider using a
more sensitive clinical staging algorithm that included such
things as PET scanning or thoracoscopy? 
Finally, I have concern regarding the complete pathologic
response rate of only 5% for this protocol. We know from
other trials in lung cancer and esophageal cancer in which the
response rates vary from 20% to 30% that only those patients
who have a pathologic CR have a survival advantage over the
rest of the group. With such a low CR rate in this trial, what
are the implications of this protocol therapy regarding sur-
vival? Is it appropriate to begin a randomized trial having
demonstrated such a poor complete clinical response rate? If
such a trial is instituted, how many patients will have to be
entered to achieve the statistical power needed to answer this
important question? 
Dr Pisters. To answer your first question about whether
this is the right subset, we excluded patients with stage IA
disease when a group of medical oncologists and thoracic
surgeons met to originally plan the trial. We did that because
the surgeons in the crowd believed that was a very favorable
subset and they did not want to subject them to the rigors of
chemotherapy before surgery. I would be quite happy to treat
them, but I think I might have problems finding those
patients. 
We included patients with T3 N0 disease because we decid-
ed to include patients with early-stage lung cancer up to the
N2 classification. We believed that the literature had demon-
strated a survival benefit for combined modality therapy in
patients with N2 disease, but it was less clear for patients with
earlier stage disease, and that is why the patients with T3 N0
and N1 disease were entered. 
In terms of the clinical and pathologic staging, that is a
point that we tried to emphasize in the article. This decision
is made based on clinical staging, and there is such a differ-
ence in survivals between patients who have clinical staging
and surgical staging. Furthermore, as our experience has
demonstrated, clearly many of the patients who we believed
had early-stage disease had a pathologic stage that was real-
ly much more advanced.
In the randomized trial it has been proposed that PET scan-
ning will be used as a companion study both at the onset of
clinical staging and again before surgery to look at whether
PET scanning accurately predicts clinical response and patho-
logic response. We did not address the use of thoracoscopy for
staging. I would defer on that issue to my surgical colleagues.
I was disappointed that the pathologic CR rate was only
5%. There were many other patients who had significant
pathologic responses seen that did not qualify as pathologic
CRs in which 75% or 80% of the resected specimen was
necrotic. I agree that pathologic CR is a very important pre-
dictor for long-term survival, especially in patients who have
only received chemotherapy before surgery as opposed to
patients who have had chemotherapy and radiation before
surgery, where I think that sterilization of the tumor after
radiation does not have that same translation to long-term
survival and control.
In the randomized trial we will be using 3 cycles of
chemotherapy before surgery, hoping that we will convert a
few more patients from histologic downstaging to complete
sterilization, and I believe that the statistical section calls for
approximately 600 patients to enter that randomized trial.
Dr David J. Sugarbaker (Boston, Mass). Dr Pisters, you
mentioned the clinical identification of N1 disease. In the
absence of PET scanning, how did you determine that
patients did indeed have N1 disease?
Dr Pisters. To qualify for the trial, all patients underwent
a mediastinoscopy. Therefore, even if they had CT evidence
of mediastinal lymph node enlargement, if their medi-
astinoscopy result was negative, we determined that they
were N2 negative. N1 involvement was determined by re-
viewing the CT scan and the mediastinal windows and was
defined as the presence of bronchopulmonary or hilar lymph
nodes that were greater than 1 cm.
Dr Sugarbaker. Because we know that enlarged mediasti-
nal nodes on CT scan will be benign at the time of medi-
astinoscopy roughly 40% to 50% of the time, I think most of
us would expect that the same would hold true for N1
adenopathy. Therefore I am wondering whether that might be
a confounding element here.
Dr Pisters. I agree, but I do not know how we can address
that other than by doing what we did. I guess the use of PET
scanning may be helpful and will be done in the randomized
trial.
Dr Sugarbaker. I have one further follow-up question.
With such a dismal CR rate, have you considered adding
radiotherapy up front? 
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 3
Pisters et al 439
Dr Pisters. I think that the use of radiation before a defin-
itive resection just makes it harder for the surgeon to remove
the tumor. I am not sure that radiation, which is another form
of local control, is really going to help when most of these
patients die of systemic recurrence and metastases. 
Dr Tom K. Waddell (Toronto, Ontario, Canada). Given
phase I and phase II trials demonstrating no increased effica-
cy of the chemotherapy regimen used in this study compared
with cisplatin-based regimens, can you comment on the rela-
tive cost of your chemotherapy regimen? 
Dr Pisters. When this trial was designed, it fell on the
heels of an American Society of Clinical Oncology meeting
in which there had been a lot of phase II data presenting the
combination of paclitaxel and carboplatin that appeared very
promising, and some of those trials were multicenter trials.
There was heated discussion among the medical oncologists
present about what the optimum chemotherapy would be.
Subsequent phase III trials comparing paclitaxel and carbo-
platin to cisplatin-based regimens have really demonstrated
equivalence in terms of both response and survival. There-
fore there is no clear winner, and there is no clear loser.
Many people have adopted paclitaxel and carboplatin, at
least in the United States, as their front-line therapy for
NSCLC because it can be administered once every 3 weeks
and is generally well tolerated. Cost is an issue, and it is
interesting that as time goes on, the other pharmaceutical
companies are raising the cost of their medicines to be
equivalent to what people are paying for the paclitaxel and
carboplatin.
Dr Scott J. Swanson (Boston, Mass). Do you have any
information available regarding the reason why 8 patients
underwent incomplete resection in this early-stage group?
Dr Pisters. In general, the reason was diseased margins,
but I do not have specific data on all 8 patients. 
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